Foghorn Therapeutics is a biotechnology company that is focused on discovering and developing novel medicines to treat cancer and other serious diseases. The company's proprietary Gene Traffic Control platform is designed to identify and target key genetic drivers of disease, with the goal of developing highly effective and targeted therapies. Foghorn Therapeutics is led by a team of experienced biotech executives and scientists, and has partnerships with leading academic institutions and pharmaceutical companies. The company is headquartered in Waltham, Massachusetts.